KR100414393B1 - Manufacturing Method for Tea and Beverage Using Rosa rugosa Thunberg - Google Patents
Manufacturing Method for Tea and Beverage Using Rosa rugosa Thunberg Download PDFInfo
- Publication number
- KR100414393B1 KR100414393B1 KR10-2001-0001897A KR20010001897A KR100414393B1 KR 100414393 B1 KR100414393 B1 KR 100414393B1 KR 20010001897 A KR20010001897 A KR 20010001897A KR 100414393 B1 KR100414393 B1 KR 100414393B1
- Authority
- KR
- South Korea
- Prior art keywords
- tea
- weight
- activity
- distilled water
- extract
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 235000013361 beverage Nutrition 0.000 title description 13
- 240000006066 Rosa rugosa Species 0.000 title description 2
- 235000000659 Rosa rugosa Nutrition 0.000 title description 2
- 230000034659 glycolysis Effects 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 18
- 240000008042 Zea mays Species 0.000 claims abstract description 15
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 15
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 15
- 235000005822 corn Nutrition 0.000 claims abstract description 15
- 235000021329 brown rice Nutrition 0.000 claims abstract description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 13
- 235000015203 fruit juice Nutrition 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 10
- 229930003268 Vitamin C Natural products 0.000 claims description 10
- 235000019154 vitamin C Nutrition 0.000 claims description 10
- 239000011718 vitamin C Substances 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 238000010025 steaming Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 14
- 239000000843 powder Substances 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 114
- 244000269722 Thea sinensis Species 0.000 abstract description 57
- 239000000284 extract Substances 0.000 abstract description 56
- 235000013616 tea Nutrition 0.000 abstract description 52
- 230000000694 effects Effects 0.000 abstract description 43
- 238000012360 testing method Methods 0.000 abstract description 31
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 27
- 230000002401 inhibitory effect Effects 0.000 abstract description 20
- 230000001093 anti-cancer Effects 0.000 abstract description 15
- 230000005965 immune activity Effects 0.000 abstract description 13
- 230000003078 antioxidant effect Effects 0.000 abstract description 12
- 230000000845 anti-microbial effect Effects 0.000 abstract description 11
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 239000000469 ethanolic extract Substances 0.000 abstract description 9
- 235000013339 cereals Nutrition 0.000 abstract description 8
- 230000003013 cytotoxicity Effects 0.000 abstract description 7
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 7
- 239000003963 antioxidant agent Substances 0.000 abstract description 5
- 238000003556 assay Methods 0.000 abstract description 5
- 230000000975 bioactive effect Effects 0.000 abstract description 5
- 239000003471 mutagenic agent Substances 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 235000019750 Crude protein Nutrition 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 235000019629 palatability Nutrition 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 230000009422 growth inhibiting effect Effects 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 abstract description 3
- 238000009826 distribution Methods 0.000 abstract description 2
- 230000010030 glucose lowering effect Effects 0.000 abstract description 2
- 230000002440 hepatic effect Effects 0.000 abstract description 2
- 231100000707 mutagenic chemical Toxicity 0.000 abstract description 2
- 230000003505 mutagenic effect Effects 0.000 abstract description 2
- 239000002245 particle Substances 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 2
- 240000004385 Centaurea cyanus Species 0.000 abstract 1
- 235000005940 Centaurea cyanus Nutrition 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 230000000871 hypocholesterolemic effect Effects 0.000 abstract 1
- 230000036543 hypotension Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 80
- 239000012153 distilled water Substances 0.000 description 61
- 230000000875 corresponding effect Effects 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 25
- 230000001953 sensory effect Effects 0.000 description 24
- 235000013399 edible fruits Nutrition 0.000 description 21
- 238000000605 extraction Methods 0.000 description 17
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 13
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 13
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 238000010998 test method Methods 0.000 description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000002414 glycolytic effect Effects 0.000 description 10
- 230000003908 liver function Effects 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 9
- 229930091371 Fructose Natural products 0.000 description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 229960002737 fructose Drugs 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 201000005202 lung cancer Diseases 0.000 description 9
- 208000020816 lung neoplasm Diseases 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000000600 sorbitol Substances 0.000 description 9
- 241000512259 Ascophyllum nodosum Species 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 235000009569 green tea Nutrition 0.000 description 8
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000005715 Fructose Substances 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 7
- 238000003210 sulforhodamine B staining Methods 0.000 description 7
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 235000008504 concentrate Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 231100000299 mutagenicity Toxicity 0.000 description 6
- 230000007886 mutagenicity Effects 0.000 description 6
- 235000005979 Citrus limon Nutrition 0.000 description 5
- 244000131522 Citrus pyriformis Species 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 4
- 235000004347 Perilla Nutrition 0.000 description 4
- 244000124853 Perilla frutescens Species 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 108010028144 alpha-Glucosidases Proteins 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000002825 functional assay Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 235000004626 essential fatty acids Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000011990 functional testing Methods 0.000 description 3
- 229910052602 gypsum Inorganic materials 0.000 description 3
- 239000010440 gypsum Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- QSMRHXUZHXEHBK-AWEZNQCLSA-N (2s)-2-[3-(furan-2-yl)prop-2-enoylamino]-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)C=CC=1OC=CC=1)C1=CC=CC=C1 QSMRHXUZHXEHBK-AWEZNQCLSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 235000011511 Diospyros Nutrition 0.000 description 2
- 244000055850 Diospyros virginiana Species 0.000 description 2
- 241001672695 Discus macclintocki Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 206010033546 Pallor Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019784 crude fat Nutrition 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- -1 1-3% by weight Chemical compound 0.000 description 1
- AFQPSLVGGMCBOR-JLTXGRSLSA-N 2-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-(2,2-dimethyl-6-methylidenecyclohexyl)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-1,3,3-trimethylcyclohexene Chemical compound C\C(\C=C\C=C(/C)\C=C\C1C(=C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C AFQPSLVGGMCBOR-JLTXGRSLSA-N 0.000 description 1
- RPGHVYBASYOTOU-AWEZNQCLSA-N 2-[[2-[[(2S)-2-[N-[3-(furan-2-yl)prop-2-enoyl]anilino]propanoyl]amino]acetyl]amino]acetic acid Chemical compound C=1C=CC=CC=1N([C@@H](C)C(=O)NCC(=O)NCC(O)=O)C(=O)C=CC1=CC=CO1 RPGHVYBASYOTOU-AWEZNQCLSA-N 0.000 description 1
- ZDLZKMDMBBMJLI-FDMDGMSGSA-N 2-[[2-[[(2s)-2-[[(e)-3-(furan-2-yl)prop-2-enoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetic acid Chemical compound C([C@@H](C(=O)NCC(=O)NCC(=O)O)NC(=O)\C=C\C=1OC=CC=1)C1=CC=CC=C1 ZDLZKMDMBBMJLI-FDMDGMSGSA-N 0.000 description 1
- 108010048632 2-furanacryloyl-phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 240000001817 Cereus hexagonus Species 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000019677 berry fruit juice Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 230000004345 fruit ripening Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 229930187168 rugosin Natural products 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
- A23F3/32—Agglomerating, flaking or tabletting or granulating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/198—Dry unshaped finely divided cereal products, not provided for in groups A23L7/117 - A23L7/196 and A23L29/00, e.g. meal, flour, powder, dried cereal creams or extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/20—Ingredients acting on or related to the structure
- A23V2200/254—Particle size distribution
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/61—Glucose, Dextrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/612—Lactose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/708—Vitamin C
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Botany (AREA)
- Mycology (AREA)
Abstract
본 발명은 해당화차의 제조방법에 관한 것이다. 보다 상세하게는 해당화 부위별 생리활성 검정을 통하여 이들 생리활성물질이 함유된 해당화 착즙액 또는 추출물을 이용하여 해당화음료차, 해당화 가루를 이용하여 엽차 및 티백 그리고 해당화 과즙을 이용하여 과립차를 제조하는 방법에 관한 것이다. 해당화 잎은 조단백질 함량이 높고 에탄올로 추출시 높은 수율과, 세포독성이 적고, 돌연변이원 억제효과, 인간 암세포에 대하여 강한 생육활성 억제효과를 나타냈다. 해당화 뿌리 에탄올 추출물은 높은 혈당 강하 능을 보였고, 높은 GST 활성과 해당화의 잎, 줄기, 뿌리의 추출물들이도 항산화능 및 항균효과를 나타냈다.The present invention relates to a method for manufacturing a tea. More specifically, the method of producing granular tea using the corresponding tea beverages, extracts of tea and tea bags using the corresponding powdered juices or extracts, using the corresponding juices or extracts containing these bioactive substances, according to the bioactive assays for the corresponding regions It is about. Glycolysed leaves showed high crude protein content, high yield and low cytotoxicity when extracted with ethanol, mutagen inhibitory effect, and strong growth inhibitory effect against human cancer cells. Glycolic root ethanol extract showed high glucose-lowering ability, and high GST activity and extracts of leaves, stems, and roots of Glycobacterium showed antioxidant and antimicrobial effects.
해당화 엽차 제조시 해당화 잎을 열처리한 경우 색깔 및 관능이 양호하고, 해당화 30%, 현미 65%, 옥수수 5%로 제조한 곡류엽차에서 기호도가 양호하게 나타났다. 해당화 티백제조시 입도분포가 조밀할수록 추출물의 색이 짙으나 관능검사에서는 150mesh이상으로 분쇄한 입자가 좋은 것으로 나타났다. 또한 해당화 뿌리 62.5% 첨가한 티백 추출물의 기능성을 검정한 결과 혈당강하 68%, 면역활성 123, 항암활성이 49%로 나타났다.When heat-treated leaves of glycolysis, the color and sensuality were good, and palatability was good in grains made from cornflower 30%, brown rice 65% and corn 5%. The more dense the particle size distribution was, the darker the color of the extract was. In addition, as a result of testing the functionality of the tea bag extract added with 62.5% of the roots, the blood sugar drop was 68%, the immune activity was 123, and the anticancer activity was 49%.
본 발명은 당뇨병치료, 항염증, 진경작용, 혈당강하작용, 혈청 콜레스테롤치 저하작용, 혈압강하작용, 간장중의 중성지방 감소효과와 혈청중성 지방의 증가억제 작용 등이 있는 해당화를 이용한 기능성식품을 제공하는 것을 목적으로 한다.The present invention provides a functional food using glycolysis, such as diabetes treatment, anti-inflammatory, myrrhosis, hypoglycemic action, hypocholesterolemic action, hypotension, hepatic triglyceride reduction effect and serum triglyceride increase effect It aims to provide.
Description
본 발명은 해당화차의 제조방법에 관한 것이다. 보다 상세하게는 해당화 부위별 생리활성 검정을 통하여 이들 생리활성물질이 함유된 해당화 착즙액을 이용하여 해당화음료차, 해당화 가루를 이용하여 엽차 및 티백 그리고 해당화 과즙을 이용하여 과립차를 제조하는 방법에 관한 것이다.The present invention relates to a method for manufacturing a tea. More specifically, the method for producing granular tea using the corresponding tea drink tea, the tea and tea bags using the corresponding powdered juice, and the granulated tea using the corresponding juice, using the corresponding juice containing these bioactive substances, according to the corresponding bioactive assay for each site of glycolysis. will be.
해당화(Rosa rugosaThunberg)는 장미과 낙엽관목으로 키가 1.5m가량 자라며 줄기와 가시에 유털이 있고 꽃은 5-7개 홍자색으로 가지의 끝에 1-3개가 달리며 향기가 짙다. 잎과 주름살이 적고 열매가 작은 것을 개해당화, 겹꽃잎인 것을 겹해당화, 가지에 가시가 거의 없고 잎에 주름살이 적은 것을 민해당화 라고 하며 한국, 일본, 만주, 캄차카반도 등의 해안지대와 얕은 산간 지대에서 자생한다. 적색으로 익는 열매 또한 매우 크며 감상가치가 높을 뿐만 아니라 식용하기도 하고 차나 쨈을 만들기도 하는데 특히 비타민C가 풍부하다. Rosa rugosa Thunberg is a rose and deciduous shrub that grows about 1.5m tall, has hairs on stems and thorns, and flowers are 5-7 reddish purple with 1-3 flowers hanging on the ends of branches. Small leaves, small wrinkles, small fruit, dog hawaminization, double petals, double hawa, small branches with few thorns and small wrinkles are called minhaegwa, and coastal areas such as Korea, Japan, Manchuria, Kamchatka Peninsula and shallow mountains It grows wild in the zone. The fruit ripening in red is also very large and has a high appreciation value. It is also edible and makes tea or sap, especially rich in vitamin C.
해당화 꽃은 토혈 풍비, 월경과다 등에 이용되고 있으며 중국에서도 간위기통, 신구풍비, 토혈, 객혈을 치료하는 데 사용하며 해당화의 지하부는 오랫동안 당뇨병 치료의 민간요법으로 널리 쓰이고 있으며, 근래에는 이 추출물이 지질대사 개선 및 혈압강하효과 등이 동물실험으로부터 확인되고 있어 이에 따른 해당화 뿌리의 유효성분을 구명하는 연구가 진행되고 있다. 최용순 등은 최근 흰쥐에 해당화 뿌리의 메탄올 추출물을 경구 투여시 간장 중성지방의 현저한 감소효과가 있음을 밝혔다. 박종철 등은 민간 생약을 대상으로 간암세포에 대한 세포독성효과를 검색하던 중 해당화의 줄기 및 잎의 덕성작용을 관찰하였다. 또한 생리활성작용에 관해서는 허 등이 지하부에서 얻은 부탄올 분획물이 항염증 및 진통작용이 있음을 보고하였으며, 송 등은 물 엑기스가 실험적으로 고혈당을 일으킨 흰쥐에서 혈당치를 감소시키는 효과가 있음을 보고하였다.The flower is used in the erythematosus, excessive menstruation, and in China, it is used to treat liver pain, new and old rain, hemostasis and hemoptysis. The underground part of the flower has been widely used as a folk remedy for the treatment of diabetes for a long time. Improvement of lipid metabolism and blood pressure lowering effects have been confirmed from animal experiments. Recently, oral administration of methanol extract from the root of Glycaceae in rats revealed a significant reduction in hepatic triglycerides. Park, Jong-Cheol et al., While searching for cytotoxic effects on liver cancer cells in folk medicines, observed virulence of glycolysis and stem. As for physiological activity, Huh et al. Reported that butanol fractions obtained from the basement had anti-inflammatory and analgesic effects, and Song et al. Reported that water extracts had the effect of reducing blood glucose levels in rats with experimentally high blood sugar. .
해당화 성분의 화학적 연구로는 과실에서 β,γ-카로틴, 포도당, 과당, 키실로스, 설탕 및 비타민 C, 꽃에서는 루고신(rugosin) A-G가 엽에서는 쿼세톨(quercetole), 이소쿼세틴(isoquercetin), 및 루틴(rutin), 지하부에서는 쿼세틴, 스테롤(sterol)이 함유되어 있다. 또한 생리활성 연구로는 항염증, 진경작용, 혈당강하작용, 혈청 콜레스테롤치 저하작용, 혈압강하작용, 간장중의 중성지방 감소효과와 혈청 중성 지방의 증가억제 작용 등이 알려져 있다.Chemical studies of glycolytic components include β, γ-carotene, glucose, fructose, xylose, sugar and vitamin C in fruit, rugosin AG in flowers, quercetole, isoquercetin, And rutin, subterranean quercetin and sterol. In addition, physiological activities are known to be anti-inflammatory, myrrhosis, hypoglycemic action, lowering serum cholesterol, lowering blood pressure, reducing triglycerides in the liver and inhibiting the increase of serum triglycerides.
본 발명은 해당화 부위별 생리 활성 검정을 통하여 해당화의 생리활성물질을 이용한 음료, 쥬스, 엽차, 액상차, 과립차, 티백 등과 같은 기능성식품을 제공하는것을 목적으로 한다.It is an object of the present invention to provide a functional food such as beverage, juice, green tea, liquid tea, granular tea, tea bag, etc. using the bioactive substance of glycolysis through the corresponding physiological activity assay.
본 발명은 해당화의 일반성분 분석, 기능성 검정 및 해당화차의 제조방법으로 구성되어 있다.The present invention consists of the general component analysis of functionalization, functional assay, and a method for producing a corresponding tea.
＜재료 및 방법＞<Materials and methods>
본 발명에서 사용된 해당화는 강원도 고성군에서 수확된 생체 또는 건조시료를 사용하였고, 부재료로 들어가는 포도당, 유당, 비타민 C, 각종 농축액 등은 식품첨가물용을 사용하였다.As the glycolysis used in the present invention, a biological or dry sample harvested from Goseong-gun, Gangwon-do, was used, and glucose, lactose, vitamin C, various concentrates, etc., used as additives were used for food additives.
＜일반성분 분석＞<General component analysis>
일반성분은 AOAC법에 따라 수분, 조단백질, 조지방, 조회분, 조섬유를 정량하였고, 해당화 부위별로 열수 및 에탄올 추출물을 다음의 표 1, 2, 3에 나타냈다.As a general component, water, crude protein, crude fat, crude ash, crude fiber were quantified according to the AOAC method, and hot water and ethanol extracts were shown in Tables 1, 2, and 3 below.
표 1. 해당화의 일반성분(단위 : %)Table 1. General Components of Correspondence (Unit:%)
해당화 잎의 경우 조단백질이 13.60%로 높은 함량을 나타내었다.In the case of glycolysis leaves, crude protein was 13.60%.
표 2. 해당화의 무기성분(단위 : %)Table 2. Inorganic Components of Correspondence (Unit:%)
표 3. 고형분(엑기스) 추출수율( % )Table 3. Extraction Yield (%)
해당화 부위별 추출수율은 잎을 에탄올로 추출할 경우 13.47%로 수율이 가장 높았으며, 그 다음으로 뿌리를 증류수로 추출하였을 때 추출수율이 12.23%로 나타났다.The extraction yield of the glycolytic sites was the highest when the leaves were extracted with ethanol (13.47%), and the extraction yield was 12.23% when the roots were extracted with distilled water.
＜기능성 검정＞<Functional test>
기능성 검정은 항암 및 세포독성, 항 돌연변이, 혈당강하, 고혈압 저해, 간기능 개선, 면역활성, 항산화, 항균 등을 검정하였다.Functional assays tested anti-cancer and cytotoxicity, anti-mutation, hypoglycemia, hypertension inhibition, liver function improvement, immune activity, antioxidant, antibacterial.
1) 항암 활성 및 세포독성 검정1) Anticancer Activity and Cytotoxicity Assay
본 실험에 이용된 세포주는 암세포로 인간 간암세포인 Hep3B (hepatocellular carcinoma, human), 인간 폐암세포인 A549(Lung carcinoma, human), 인간 유방암세포인 MCF7(brest adenocarcinoma, pleural effusion,human)을 사용하였고 시료 자체의 세포 독성을 알아 보기 위한 정상세포로는 인간 정상 간세포인 WRL68(Human embryo liver)을 사용하였다. 실험에 사용된 세포들 중 Hep3B, MCF7, WRL68 은 DMEM배지를 A549는 RPMI 1640배지에서 10% 가열비활성화 FBS(fetal bovin serum)으로 적응시켜 배양하였다.The cell lines used in this experiment were Hep3B (hepatocellular carcinoma, human), human lung cancer cells (Lung carcinoma, human), human lung cancer cells, and MCF7 (brest adenocarcinoma, pleural effusion, human) cells. As a normal cell to check the cytotoxicity of the sample itself, human embryonic liver WRL68 (Human embryo liver) was used. Among the cells used in the experiment, Hep3B, MCF7, and WRL68 were cultured by adapting DMEM medium to 10% heat-inactivated FBS (fetal bovin serum) in RPMI 1640 medium.
아래의 표 4에 인간유방암세포(%/mg/ml), 표 5에 인간 간암세포(%/mg/ml) 및 표 6에 인간 폐암세포(%/mg/ml)에 대한 각각의 항암활성 결과를 나타내었다.Each anticancer activity results for human breast cancer cells (% / mg / ml), Table 5 human liver cancer cells (% / mg / ml) and Table 6 human lung cancer cells (% / mg / ml) below Indicated.
표 4. 항암활성; 인간유방암세포(%/mg/ml)Table 4. Anticancer Activity; Human Breast Cancer Cells (% / mg / ml)
해당화 추출물의 인간 유방암세포(MCF7)에 대한 생육억제 활성을 측정한 결과, 해당화 줄기의 에탄올 추출물이 1.0 mg/ml의 농도에서 96%의 생육 억제 효과를 나타내어 가장 높은 억제효과를 나타내었고, 해당화는 잎의 추출물을 제외하고 나머지 줄기, 뿌리, 열매 추출물들은 60%이상의 높은 항암 효과를 나타내었다.As a result of measuring the growth inhibition activity of glycolytic extract on human breast cancer cells (MCF7), the ethanol extract of glycolysis stem showed 96% growth inhibition effect at 1.0 mg / ml concentration and the highest inhibition effect Except for leaf extracts, the remaining stem, root and fruit extracts showed high anticancer effects of over 60%.
표 5. 항암활성; 인간 간암세포(%/mg/ml)Table 5. Anticancer Activity; Human liver cancer cell (% / mg / ml)
해당화 추출물의 인간 간암세포(Hep3B)에 대한 생육 억제 효과를 측정한 결과, 해당화 열매의 에탄올 추출물이 1.0 mg/ml의 농도에서 86%의 생육 억제 효과를 나타내어 가장 높았고, 해당화 추출물은 잎, 줄기, 뿌리, 열매 모두가 1.0mg/ml의 농도에서 60%이상의 높은 억제활성을 나타내었다.As a result of measuring the growth inhibitory effect on the human liver cancer cells (Hep3B) of the glycolysis extract, the ethanol extract of the glycolysis fruit showed the highest inhibitory effect of 86% at the concentration of 1.0 mg / ml. Both root and fruit showed high inhibitory activity of more than 60% at the concentration of 1.0mg / ml.
표 6. 항암활성; 인간 폐암세포(%/mg/ml)Table 6. Anticancer Activity; Human Lung Cancer Cells (% / mg / ml)
해당화 추출물의 인간 폐암세포(A549)에 대한 생육 억제 효과를 측정한 결과, 해당화 열매의 에탄올 추출물이 1.0 mg/ml의 농도에서 91%의 가장 높은 억제 효과를 나타내었고, 해당화의 나머지 추출물들도 70% 이상의 매우 높은 항암 활성을 나타내었다.As a result of measuring the growth inhibitory effect on the human lung cancer cells (A549) of the glycolysis extract, the ethanol extract of the glycolysis fruit showed the highest inhibitory effect of 91% at the concentration of 1.0 mg / ml, and the remaining extracts of the glycolysis also 70 It showed very high anticancer activity of more than%.
세포독성은 SRB(sulforhodamine B)방법으로 세포 단백질을 염색하여 세포의 증식이나 독성을 측정하는 방법으로 실험 대상 세포인 WRL68, Hep3B, MCF7(10% FBS, DMEM 배지)과 A549(10% FBS, RPMI 1640 배지)의 농도를 4∼5×104cell/㎖으로 96 well plate의 각 well에 100㎕씩 첨가하여 24시간 동안 배양(37℃, 5% CO2)한 후, 각각의 시료를 최종농도 0.2, 0.4, 0.6, 0.8, 1.0㎎/㎖로 100㎕씩 첨가하여 48시간 배양하였다. 배양이 완료된 후에 상등액을 제거하고 차가운 10%(w/v) TCA(trichloroacetic acid) 100㎕를 가하여 4℃에서 1시간동안 방치한 후 증류수로 4∼5회 세척하여 TCA를 제거하고 실온에서 플레이트를 건조한 후, 각 well에 1%(v/v) 초산에 녹인 0.4%(w/v) SRB용액을 100㎕씩 첨가하고 상온에서 30분 동안 염색시켰다. 결합되지 않은 SRB 염색액은 1% 초산으로 4∼5회 정도 세척, 건조시킨 후에 10mM Tris buffer 100㎕를 첨가하여 염색액을 녹여낸 후 540nm에서 마이크로플레이트 판독기(microplate reader)를 이용하여 흡광도를 측정하여 그 결과를 다음의 표 7에 나타냈다.Cytotoxicity is a method of measuring cell proliferation or toxicity by staining cellular proteins by SRB (sulforhodamine B) method. The cells to be tested are WRL68, Hep3B, MCF7 (10% FBS, DMEM medium) and A549 (10% FBS, RPMI). 1640 medium) at a concentration of 4-5 × 10 4 cells / ml and 100 μl of each well of a 96 well plate, followed by incubation for 24 hours (37 ° C., 5% CO 2 ). 100 μl each was added at 0.2, 0.4, 0.6, 0.8, 1.0 mg / ml and incubated for 48 hours. After the incubation was completed, the supernatant was removed, 100 μl of cold 10% (w / v) trichloroacetic acid (TCA) was added thereto, and left at 4 ° C. for 1 hour, followed by 4 to 5 washes with distilled water to remove TCA. After drying, 100 µl of 0.4% (w / v) SRB solution dissolved in 1% (v / v) acetic acid was added to each well and stained at room temperature for 30 minutes. Unbound SRB dye solution was washed and dried 4 ~ 5 times with 1% acetic acid, and then, 100μl of 10mM Tris buffer was dissolved to dissolve the dye solution. The absorbance was measured at 540 nm using a microplate reader. The results are shown in Table 7 below.
표 7. 정상세포독성(%/mg/㎖)Table 7. Normal Cytotoxicity (% / mg / mL)
사람 정상 간세포인 WRL-68에 대한 세포독성을 측정한 결과, 해당화의 세포독성은 35% 미만으로 나타나 시료 자체의 독성이 매우 낮았다. 그 중 독성이 가장 높은 추출물은 해당화 줄기와 열매의 에탄올 추출물이었고, 1.0 mg/ml의 농도에서 34%의 독성을 나타냈다. 전체적으로 해당화의 모든 추출물의 세포독성이 높았다.As a result of measuring cytotoxicity against WRL-68, a normal human hepatocyte, the cytotoxicity of glycolysis was less than 35%, indicating that the sample itself was very low. Among the most toxic extracts, the ethanol extracts of the corresponding stems and fruits were 34% toxic at 1.0 mg / ml. Overall, all extracts of glycolysis were highly cytotoxic.
2) 항 돌연변이원성2) anti mutagenicity
Rec-assay법에 의하여 균주를 프랑카 자니(Franca Zani, Italy)로부터 분양받은 바실러스 서브틸리스 PB 1652 rec+(repair proficient)와 PB 1791 rec-(repair deficient)이며 동결건조된 이 균주를 클린벤치에서 메스를 이용하여 영양아가(nutrient agar)를 고화 시킨 페트리디쉬에 접종시킨 후 24∼48시간 배양을 하였다. 배양이 완료되면 멸균된 TSB 액체 배지에 1백금이 취하여 37℃에서 24시간 배양하여 실험에 사용하였다. 배양이 완료된 0.1㎖ spore 액이 첨가된 soft broth agar 10㎖를 페트리디시에 분주하여 고화시킨 후 페이퍼디스크를 올려놓고 각 추출물은 20㎕씩, 대조구인 MNNG는 10㎕ 접종하고 37℃에서 12∼24시간 배양한 후 돌연변이원성 및 항돌연변이원성을 측정하였다.Bacillus subtilis PB 1652 rec + (repair proficient) and PB 1791 rec- (repair deficient), which were distributed from Franca Zani, Italy by the Rec-assay method, were scrubbed in cleanbenches. Inoculated in a Petri dish solidified nutrient agar (nutrient agar) was incubated for 24 to 48 hours. When the incubation was completed, platinum was added to sterile TSB liquid medium and incubated at 37 ° C. for 24 hours to use in the experiment. Incubate 10 ml of soft broth agar with 0.1 ml spore solution, incubated in Petri dish, and solidify it. Then, put up a paper disk, 20 µl of each extract, 10 µl of MNNG control, inoculate 12-24 at 37 ℃. Mutagenicity and antimutagenicity were measured after time incubation.
돌연변이원성은 무균 상태인 clean-bench하에서 여러 돌연변이원성 물질 중 강한 돌연변이원 물질인 MNNG(2㎍/㎕)를 돌연변이원성(DNA-damaging activity) 대조구로 하여 20㎍/paper disc의 양으로 멸균 처리된 paper disc에 첨가하였고 각 추출물을 4∼100㎍/paper disc가 되도록 첨가하고 rec(+)균과 rec(-)균에 의해 형성된 억제영역(㎝)의 차이로 돌연 변이원성을 측정하였다. 항돌연변이원성은 돌연변이원성을 확인한 후에 MNNG(10㎍/p.disc)와 추출물(50, 100㎍/p.disc)을 1 : 1 (10㎕:10㎕)로 혼합하여 돌연변이원성 측정과 같은 방법으로 배양한 후 각기 형성된 억제영역을 비교하여 각 추출물이 돌연변이원 물질인 MNNG의 돌연변이원성을 어느 정도 억제하는가를 rec(+)균과 rec(-)균의 차이영역(㎝)과 차이율(sample+MNNG / MNNG)로 나타내었다. 대조구는 MNNG만 처리한 것으로 하였다. 그 결과를 다음의 표 8에 나타냈다.The mutagenicity was sterilized in 20 µg / paper disc using a strong mutagenic substance MNNG (2 µg / µl) as a DNA-damaging activity control under sterile clean-bench. Each extract was added to 4-100 ㎍ / paper disc and the mutagenicity was measured by the difference between the inhibitory region (cm) formed by the rec (+) and rec (-) bacteria. Antimutagenicity was determined by mutagenicity, and then mixed with MNNG (10µg / p.disc) and extract (50, 100µg / p.disc) in a ratio of 1: 1 (10µl: 10µl). After the incubation with each other, the inhibitory regions formed were compared to determine how much each extract inhibits the mutagenicity of MNNG, which is a mutagenic substance, and the difference region (cm) and the difference rate (sample) between rec (+) and rec (-). + MNNG / MNNG). The control was treated only with MNNG. The results are shown in Table 8 below.
표 8. 항돌연변이Table 8. Antimutagenic
해당화에 대한 추출물(50, 100㎍/paper disc)과 MNNG(10㎍/paper disc)를 1 : 1로 혼합하여 추출물 농도에 따른 돌연변이원 억제 효과를 실험하였다. 대조구인 MNNG(20㎍/paper disc)에 비해 MNNG와 추출물이 1 : 1로 혼합된 것이 비교적 높은 항돌연변이원성을 보였고, rec(+)와 rec(-)의 돌연변이가 일어난 영역 지름의 차이로 대조구(MNNG)와 비교하여 항돌연변이원성을 알아낼 수가 있다. 대조구로 쓰인 강력한 돌연변이원성 물질인 MNNG를 기준으로 나머지 추출물의 항돌연변이원성을 측정한 결과 해당화 잎 에탄올 추출물이 MNNG에 비해서 100㎍/paper disc의 농도에서 70%의 가장 높은 돌연변이 억제율을 보였고, 나머지 추출물들도 40% 이상의 억제율을 나타내었다. 이러한 항돌연변이원성은 해당화, 다시마 추출물들이 MNNG와 균주의 DNA, RNA와의 결합을 어느 정도 억제함으로서 항돌연변이원성을 지닌다고 추론할 수 있다.Mixture extract (50, 100 ㎍ / paper disc) and MNNG (10 ㎍ / paper disc) for glycolysis were mixed at a ratio of 1: 1, and the mutagen inhibitory effects of the extract concentrations were tested. Compared with the control MNNG (20㎍ / paper disc), the mixture of MNNG and extract 1: 1 showed a relatively high antimutagenicity, and the control was caused by the difference in the diameter of the rec (+) and rec (-) mutations. Compared to MNNG, antimutagenicity can be identified. Antimutagenicity of the remaining extracts was determined based on MNNG, a potent mutagenic substance used as a control, and the resultant ethanol extract showed the highest mutation inhibition rate of 70% at the concentration of 100㎍ / paper disc compared to MNNG. Also showed an inhibition rate of 40% or more. This antimutagenicity can be inferred that the glycolysis, kelp extracts have antimutagenicity by inhibiting the binding of MNNG to the DNA and RNA of the strain to some extent.
3) 혈당 강하 기능 측정3) Blood glucose lowering function measurement
생체 내에서 혈당 상승의 결정적인 역할을 하는 α-글루코시다제를 이용하여 실험을 수행하였다. 먼저 효소를 10mM PIPES buffer에 용해시켜 효소액을 제조하고 20mM 말토스와 각 추출물을 각각 10㎕, 40㎕, 10㎕를 혼합하여 최종 부피를 60㎕로 각 추출물을 농도별로 혼합한 후 37℃에서 20분간 배양한다. 반응액 60㎕에 1㎖ DNS 시약을 첨가하고 100℃ 물에서 열탕 처리(10min)하여 반응을 정지시킨 후에 540nm에서 흡광도를 측정하여 효소 반응으로 생성된 환원당을 정량하여 각 추출물을 처리하지 않은 대조구와 비교하여 효소활성 저해율을 계산하여 그 결과를 다음의 표 9에 나타냈다.Experiments were performed using α-glucosidase, which plays a critical role in raising blood glucose levels in vivo. First, the enzyme was prepared by dissolving the enzyme in 10 mM PIPES buffer, and then, 10 μl, 40 μl, and 10 μl of 20 mM maltose and each extract were mixed. Incubate for minutes. 1 ml DNS reagent was added to 60 µl of the reaction solution, and the reaction was stopped by boiling water treatment (10 min) at 100 ° C. water, and then absorbance was measured at 540 nm. In comparison, the enzyme activity inhibition rate was calculated and the results are shown in Table 9 below.
표 9. 혈당강하(α-glucosidase) (%/mg/ml)Table 9. Blood Glucose (α-glucosidase) (% / mg / ml)
α-글루코시다제는 생체내 혈당 상승에 결정적인 역할을 수행할 뿐만 아니라 다양한 대사장애와 당뇨병, 바이러스성질병, 세균감염, 암형성에 관여한다. 본 실험에서는 기질(maltose)과 해당화, 다시마 추출물들을 첨가해서 추출물에 의한 효소 활성 억제율을 검색한 것으로 결과, 해당화 추출물의 경우 전체적으로 60%이상의 억제율을 보였고, 특히 해당화 뿌리 에탄올 추출물의 1.0 mg/ml 농도에서 80%로 가장 높은 혈당강하능을 보여 당뇨 조절을 위한 기능성 식품으로의 활용이 가능할 것으로 판단된다.α-glucosidase not only plays a crucial role in raising blood glucose in vivo, but is also involved in various metabolic disorders and diabetes, viral diseases, bacterial infections, and cancer formation. In this experiment, the inhibitory activity of enzyme activity by extract was added by adding maltose, glycolysis and kelp extracts. As a result, the inhibition rate of glycolysis extract was over 60%, especially 1.0 mg / ml concentration of glycolysis root ethanol extract. It shows the highest hypoglycemic ability at 80% in the future, so it can be used as a functional food for controlling diabetes.
4) 고혈압 저해능 측정4) Determination of hypertension inhibition
ACE(angiotensin converting enzyme)는 고혈압을 유도하는 효소이므로 이 효소의 억제 활성을 측정하기 위해 ACE 시약을 사용했다. 실험 전에 모든 반응물을 37℃로 유지시켜 놓은 후 37℃ 증류수 10㎖에 ACE 시약 1바이알을 용해시키고 1㎖씩 취하여 튜브에 넣었다. 각 튜브에 농도별 추출물과 ACE 캘리브레이터를 100㎕씩 첨가한 후 37℃에서 5분간 반응시켜 340nm에서 흡광도를 측정하여 이것을 초기 A 값으로 정하고 다시 5분이 지난 후 측정한 흡광도를 최종 A라 정하였다. 대조구로는 추출물 대신 증류수 100㎕를 첨가한 것으로 하였다. Control의 ACE(U/L) 값은 아무 것도 첨가하지 않았을 때의 흡광도 변화를 측정한 것으로 하였으며 ACE의 활성 계산은 다음 공식에 준하여 산출하여 그 결과를 다음의 표 10에 나타냈다.Since angiotensin converting enzyme (ACE) is an enzyme that induces hypertension, ACE reagent was used to measure the inhibitory activity of the enzyme. Before the experiment, all the reactants were maintained at 37 ° C., 1 vial of ACE reagent was dissolved in 10 ml of 37 ° C. distilled water, and 1 ml each was taken into a tube. 100 μl of extract and ACE calibrator for each concentration were added to each tube, and then reacted at 37 ° C. for 5 minutes, and the absorbance was measured at 340 nm. This was determined as the initial A value and the absorbance measured after 5 minutes was determined as final A. As a control, 100 μl of distilled water was added instead of the extract. The ACE (U / L) value of the control was measured by the change in absorbance when nothing was added. The activity calculation of the ACE was calculated according to the following formula and the results are shown in Table 10 below.
ACE (U/L) = (Initial A - Final A)test/ (Initial A - Final A)control×ACE (U / L) = (Initial A-Final A) test / (Initial A-Final A) control ×
active of ACE reagent (50U/L)active of ACE reagent (50U / L)
표 10. 고혈압(ACE-system) (%/mg/ml)Table 10. ACE-system (% / mg / ml)
생체 내에서 혈압 상승의 주요 기작은 레닌 안지오텐신 시스템이 주요 역할을 하는데 ACE는 레닌에 의해 안지오텐신 Ⅰ의 히스티딜루이신 디펩티드를 분해하여 강력한 혈관 수축 작용을 일으키는 바소콘드릭터(vasocontrictor)인 안지오텐신 Ⅱ로 전환을 유도하는 효소이고 안지오텐신 Ⅱ는 신체 내에서 알도스테린의 분비를 촉진함으로써 물과 나트륨의 배설을 억제하며 혈관 이완 작용을 가진 브래디키닌(bradykinin)을 불활성화 시킴으로 결과적으로 혈압을 상승시키는 역할을 한다. 따라서 직접적으로 ACE를 억제하면 고혈압의 치료가능성이 제시될 수 있다고 볼 수 있고 실제로 정상인에게도 현저한 혈압 강하 작용이 밝혀졌다. 본 실험에서는 ACE가 FAPGG(Furylacryloyl phenylalanylglycylglycine)를 FAP (Furylacryloylphenyl alanine)와 GG (glycylglycine)로 분해하는 원리를 이용한것으로 해당화, 다시마 추출물에 의한 ACE억제 정도를 측정하였다. 측정결과, 해당화 뿌리 추출물들이 높은 억제능을 나타내어 1.0 mg/ml의 농도에서 80%에 가까운 매우 높은 고혈압 억제능을 보였다.The main mechanism of blood pressure rise in vivo is the renin angiotensin system, which plays an important role in ACE. It is an enzyme that induces conversion and angiotensin II inhibits the excretion of water and sodium by promoting the release of aldosterin in the body and inactivates bradykinin, which has a vasorelaxing effect, and consequently elevates blood pressure. do. Therefore, direct inhibition of ACE could suggest the possibility of treatment of hypertension. In this experiment, ACE decomposes FAPGG (Furylacryloyl phenylalanylglycylglycine) into FAP (Furylacryloylphenyl alanine) and GG (glycylglycine). As a result of the measurement, the extracts of the corresponding roots showed a high inhibitory activity, showing a very high hypertension inhibitory ability of nearly 80% at the concentration of 1.0 mg / ml.
5) 간 기능 개선 활성 측정5) Liver function improvement activity measurement
(1) 해독작용 - Glutathione S-transferase 측정(1) Detoxification-Determination of Glutathione S-transferase
해당화, 다시마의 해독작용 정도를 측정하기 위하여 간의 중요 해독기전 중의 하나인 GST(gultathion-S-transferase)의 활성을 측정하였다. 조제된 반응시약에 대조구로 추출물이 제외된 반응액을 대조구로 하였으며, 각 추출물을 농도별로 첨가하여 37℃에서 5분간 반응시킨 다음 기질로서 1-chloro-2,4dinitro benzene을 첨가한 후 다시 37℃에서 2분간 반응시켰다. 반응후 20% TCA를 가하여 반응을 종결시키고 원심분리한 후 상등액을 340nm에서 흡광도를 측정한 뒤 다음과 같이 GST의 specific activity와 활성율을 계산하여 다음의 표 11에 나타냈다.In order to determine the degree of detoxification of glycolysis and kelp, the activity of GST (gultathion-S-transferase), one of the liver's important detoxification mechanisms, was measured. The prepared reaction reagent was used as a control. The reaction solution without the extract was used as a control. Each extract was added at different concentrations and reacted at 37 ° C. for 5 minutes. Then, 1-chloro-2,4dinitro benzene was added as a substrate. The reaction was carried out for 2 minutes at. After the reaction, 20% TCA was added to terminate the reaction, and centrifuged. The supernatant was measured for absorbance at 340 nm, and the specific activity and activity ratio of GST were calculated as shown in Table 11 below.
Total activity (units) = (A340/ 9.6) × 희석배수 × (3ml / 0.1) ×Total activity (units) = (A 340 / 9.6) × Dilution factor × (3ml / 0.1) ×
crude extract(㎖)crude extract (ml)
Specific activity ( units/㎖ protein ) = total activity / total proteinSpecific activity (units / ml protein) = total activity / total protein
활성율 (%) = specific activitytest/ specific activitycontrol× 100% Activity = specific activity test / specific activity control × 100
표 11. 간기능개선(%/mg/ml)Table 11. Liver Function Improvement (% / mg / ml)
GST는 감소된 글루타치온에 다양한 친전자체를 결합시키는 반응을 촉매 하는 주요 해독 기전으로 많은 연구가 이루어 졌으며 또한 다양한 발암 원들이 대부분 친전자체이므로 이들 발암물질을 해독하는 경로로 중요하게 여겨진다. 따라서 GST의 활성 측정은 화학적 발암원을 해독, 불활성화시킬 수 있는 약재나 천연물질 구명에 이용될 수 있다. 본 실험의 결과는 대조군의 GST 활성은 7613.32(units/㎎ protein)이였고 추출물을 0.2, 0.4, 0.6, 0.8, 1.0g/ℓ의 농도로 첨가한 결과 해당화 잎 증류수 추출물이 1.0 mg/mℓ의 농도에서 24210.36(units/㎎ protein)로 약 3.18배의 활성을 증가 시켜 가장 높았다. 또한 여러 추출물의 경우 1.0 mg/mℓ의 농도에서 1.6배이하의 낮은 활성 증가를 나타냈다.GST has been studied as a major detoxification mechanism that catalyzes the reaction of reduced glutathione with various electrophiles. Also, since various carcinogens are mostly electrophiles, GST is considered to be an important detoxifying agent. Therefore, GST activity measurement can be used for the investigation of medicines or natural substances that can detoxify and inactivate chemical carcinogens. The GST activity of the control group was 7613.32 (units / mg protein), and the extract was added at 0.2, 0.4, 0.6, 0.8, 1.0 g / l. It was the highest by increasing the activity of about 3.18 times to 24210.36 (units / mg protein) at. In addition, several extracts showed a low activity increase of less than 1.6 fold at a concentration of 1.0 mg / ml.
6) 면역 활성 측정6) Immune activity measurement
면역이란 우리 몸의 내, 외부로부터의 자극 및 손상에 대항하는 방어기작을 총칭한다. 면역활성의 측정은 면역물질의 측정, 면역세포의 생육도 측정 등을 통하여 이루어지는데 면역 세포의 증가 및 감소는 우리 몸 면역계의 이상을 실질적으로 나타내주는 지표라 할 수 있을 것이다. 실험 면역 세포주 Raji(RPM1-1640 medium)을 접종하여 세포 정상 생육기에 도달(7일정도 소요)시킨 후 96-well Plate(5×104Cell/㎖로 농도 조절한 배지 100㎕/well)를 37℃에서 5% CO2상태로 24시간 incubation하고 각 농도로 100㎕의 시료를 투여한 후 37℃에서 5% CO2상태로 48시간 배양한 후 상등액을 제거하고 차가운 10%(w/v) TCA(trichloroacetic acid) 100㎕를 가하여 4℃에서 1시간동안 방치한 후 증류수로 4∼5회 세척하여 TCA를 제거하고 실온에서 plate를 건조한 뒤 각 웰에 1%(v/v) 초산에 녹인 0.4%(w/v) SRB용액을 100㎕씩 첨가하고 상온에서 30분 동안 염색시켰다.Immunity refers to the defense mechanism against stimulation and damage from inside and outside of our body. The measurement of immune activity is carried out through the measurement of immune substances, the growth of immune cells, etc. The increase and decrease of immune cells may be an indicator of the abnormality of our body's immune system. After inoculating the experimental immune cell line Raji (RPM1-1640 medium) to reach the normal cell growth period (takes about 7 days), 96-well plate (100 μl / well of medium adjusted to 5 × 10 4 Cells / ml) was 37 Incubate with 5% CO 2 at 24 ° C for 24 hours, inject 100 μl of sample at each concentration, incubate for 48 hours at 37 ° C with 5% CO 2 , remove supernatant and cool 10% (w / v) TCA. (trichloroacetic acid) 100 μl was added and left at 4 ° C. for 1 hour, washed 4 to 5 times with distilled water to remove TCA, dried at room temperature and 0.4% dissolved in 1% (v / v) acetic acid in each well. (w / v) 100 μl of SRB solution was added and stained at room temperature for 30 minutes.
결합되지 않은 SRB 염색액은 1% 초산으로 4∼5회 정도 세척, 건조시킨 후에 10mM Tris buffer 100㎕를 첨가하여 염색액을 녹여낸 후 540nm에서 흡광도를 측정하였다. 암세포 생육도(%) = test/control × 100는 면역세포인 Raji의 생육을 증가시키는 정도를 측정하는 것이므로 세포생육이 증가함에 해당식품이 면역력을 증가시킬 수 있음을 시사한다. 면역 기능 증강 효과는 인간 면역 세포인 B cell(Raji)을 이용하여 검증하였다. 세포의 생육은 10% FBS를 함유하는 RPMI 1640 배지에서 5% CO2, 37℃에서 배양하였으며, 면역 기능 증강 효과는 SRB assay를 사용하여 측정하여 그 결과를 표 12에 나타냈다.Unbound SRB dye solution was washed 4-5 times with 1% acetic acid and dried, and then 100 μl of 10mM Tris buffer was added to dissolve the dye solution and absorbance was measured at 540 nm. Cancer cell growth (%) = test / control × 100 is to measure the extent to increase the growth of immune cells Raji suggests that the food can increase the immunity as cell growth increases. Immune function enhancement effect was verified using B cell (Raji), a human immune cell. The growth of the cells was cultured at 5% CO 2 , 37 ℃ in RPMI 1640 medium containing 10% FBS, the immune function enhancement effect was measured using the SRB assay and the results are shown in Table 12.
표 12. 면역활성(%/mg/ml)Table 12. Immune activity (% / mg / ml)
인간 면역 체계에서 항체 생성의 중요한 역할을 하는 인간 B세포(Raji)로 SRB assay를 이용하여 실험한 결과, 각 해당화, 다시마 추추물의 농도 0.2에서 1.0 mg/mℓ까지 증가하는 것으로 나타났다. 또한 해당화 증류수 추출물이 1.0 mg/mℓ의 농도에서 1.72배의 증가로 가장 높았고, 나머지의 추출물들도 1.0 mg/mℓ의 농도에서 1.44∼1.67배까지의 증가를 나타냈다. 그리고 낮은 농도에서도 모든 추출물들이 0.2g/ℓ의 농도에서 1.03∼1.19배로 세포활성을 촉진하는 것으로 나타났다.Human B cells (Raji), which play an important role in the production of antibodies in the human immune system, were tested using SRB assay, and the concentration of each glycolytic and kelp extract increased from 0.2 to 1.0 mg / ml. Also, the distilled water extract showed the highest increase of 1.72 times at the concentration of 1.0 mg / ml, and the rest of the extracts showed the increase of 1.44 to 1.67 times at the concentration of 1.0 mg / ml. And even at low concentrations, all extracts were found to promote cell activity 1.03--1.19 times at the concentration of 0.2g / ℓ.
7) 항산화 활성 측정7) Antioxidant Activity Measurement
산화는 우리 체내에서 세포막내 손상을 일으키고 노화를 촉진하며 발암이나 성인병 등과도 밀접한 관련을 갖고 있다. 노화 및 성인병 예방의 측면에서 항산화 활성 물질이 요구되어지며 산화 억제 물질에 대한 검색으로 4.5×10-3리놀레인산 수용액 5㎖에 시료 0.5㎖를 넣어서 50℃에서 배양시키면서 마개 달린 시험관에 1.1㎖씩 4일마다 채취하여 TCA 1㎖, TBA 2㎖, BHT 0.1㎖, SDS 1㎖를 각각 혼합한 후 N2개스를 취입하고 밀봉한 후 비등 수욕조에서 15분간 배양하고 방냉시킨 후 1㎖ 초산과 2㎖ 클로포름을 혼합 진탕후 2,500rpm에서 10분간 원심분리하여 상등액을 532nm에서 흡광도를 측정한다. 리놀레인산은 필수 지방산이며 다가 불포화 지방산으로 산화되기쉽다. 그러한 리놀레인산에 대한 항산화성을 나타내는 해당식품은 노화 방지 및 성인병 예방에 효과적임을 시사한다. 산화억제물질에 대한 검색은 TBA법으로 측정하여 다음의 표 13에 나타냈다.Oxidation causes damage in cell membranes, promotes aging, and is closely related to carcinogenesis and adult diseases. Antioxidant active material is required in terms of aging and prevention of geriatric diseases. In the search for an antioxidant, 0.5 ml of the sample was added to 5 ml of 4.5 × 10 -3 linoleic acid aqueous solution and 1.1 ml of the test tube was incubated at 50 ° C. After every 4 days, 1 ml of TCA, 2 ml of TBA, 0.1 ml of BHT, and 1 ml of SDS were mixed, injected and sealed with N 2 gas, incubated in a boiling water bath for 15 minutes, and allowed to cool, followed by 1 ml of acetic acid and 2 After mixing and shaking ml chloroform, the supernatant was measured for absorbance at 532 nm by centrifugation at 2,500 rpm for 10 minutes. Linoleic acid is an essential fatty acid and easily oxidized to polyunsaturated fatty acids. These foods, which exhibit antioxidant properties against linoleic acid, are effective in preventing aging and preventing adult diseases. The search for the antioxidant inhibitor was measured by TBA method and shown in Table 13 below.
표 13. 항산화활성(%/mg/ml)Table 13. Antioxidant Activity (% / mg / ml)
필수 지방산인 리놀레인산은 다가 불포화지방산으로 산화되기 매우 쉽다. 이러한 리놀레인산에 대한 산화를 억제시키는 것은 노화방지 및 성인병 예방에 효과적일 것이다. 따라서 본 실험에서 해당화, 다시마 추출물들의 항산화활성을 측정한 결과, 해당화의 잎, 줄기, 뿌리의 추출물들이 60%이상의 항산화능을 나타내었다. 해당화의 이런 항산화능은 식물을 원료로서 식품을 제조할 경우 체내에서 필요한 식품 내 필수지방산의 산화 억제로 식품의 안정성 연장 및 흡수시 체내 활성 라디칼의 소거 등의 작용으로 노화억제 및 체내 산화작용으로 발생하는 성인병 등의 예방에 효과적일 것으로 생각되었다.Linoleic acid, an essential fatty acid, is very susceptible to polyunsaturated fatty acids. Inhibiting the oxidation of such linoleic acid will be effective in preventing aging and preventing adult diseases. Therefore, as a result of measuring the antioxidant activity of the glycolysis, kelp extracts in this experiment, the extracts of the leaves, stems, roots of glycolysis showed more than 60% antioxidant activity. This antioxidant activity of glycolysis occurs by inhibiting aging and oxidizing the body by action of prolonging the stability of food by oxidizing essential fatty acid in the food which is needed in the body when food is produced from plants as raw material and eliminating active radicals in the body when absorbing. It was thought to be effective in preventing adult diseases.
8) 항균 활성 측정8) Antimicrobial Activity Measurement
항균력 검색은 공시균주로서 그람음성세균(Gram positive bacteria;Listeria monocytogenes, Bacillus subtilis, Staphylocoocus aureus),그람양성세균(Gram negative bacteria;Salmonella typhimurium, Escherichia coli, Pseudomonas aeruginosa)을 배지(Tryptic soy broth and agar)에서 검색방법(paper disc, bioscreen C)으로 항균력 검색한다. 항균력 검색은 TSB배지를 121℃에서 15분간 살균한 후 냉각하여 무균적으로 페트리디시에 15ml씩 분주하여 무균상에서 하룻밤 방치하여 굳힌 후 준비된 피검균 배양액 0.1ml를 평판배지에 주입하여 균일하게 도포한다. 각 시료를 멸균된 8.0mm 여과지디스크(Whatman No.2)에 농도별로 흡수시킨 후 시험용 평판배지에 올려놓고 난 다음, 30℃의 인큐베이터에서 24-48시간 배양하면서 디스크주변의 명확한 영역(mm)을 측정하여 항균력을 조사하여 그 결과를 아래의 표 14에 정리하여 나타내었였다.Antimicrobial activity search was carried out using Gram positive bacteria ( Listeria monocytogenes, Bacillus subtilis, Staphylocoocus aureus), Gram negative bacteria ( Salmonella typhimurium, Escherichia coli, Pseudomonas aeruginosa ) as a test strain. Search for antimicrobial activity in the search method (paper disc, bioscreen C). The antimicrobial activity test was performed by sterilizing TSB medium at 121 ° C. for 15 minutes, cooling and aseptically dispensing 15 ml each of Petri Dish, leaving it to stand overnight in aseptic phase, and injecting 0.1 ml of the prepared culture medium into a flat medium and applying it uniformly. Each sample was absorbed by sterilized 8.0mm filter paper disc (Whatman No. 2) and placed on a test plate medium, and then incubated in a incubator at 30 ° C for 24-48 hours, and the clear area (mm) around the disc was made. The antimicrobial activity was measured and the results were summarized in Table 14 below.
최소저해농도 측정은 각 시료를 0.45㎛의 멤브레인필터(Whatman No.2)로 제균하고 농도별로 멸균한 브로스에 첨가한다. 전배양된 각 균의 농도를 105CFU/㎖되도록 접종하여 바이오스크린 C로 35℃에서 24시간 배양하면서 피검균의 생육을 O.D값으로 측정하여 그 결과를 다음의 표 15에 나타냈다.In order to measure the minimum inhibitory concentration, each sample is sterilized with a membrane filter (Whatman No. 2) of 0.45 µm and added to the sterilized broth by concentration. The inoculation was carried out so that the concentration of each of the pre-cultured bacteria to 10 5 CFU / ㎖ and incubated for 24 hours at 35 ° C with Bioscreen C to measure the growth of the test bacteria as OD value and the results are shown in Table 15 below.
표 14. 항균활성; 항균력(mm: 5mg/disc)Table 14. Antibacterial activity; Antimicrobial Activity (mm: 5mg / disc)
*LM :L. monocytogenesATCC 19111 BC :B. cereusKCCM 11204 * LM: L. monocytogenes ATCC 19111 BC: B. cereus KCCM 11204
SA :Staphy. aureusKCCM 32395 ST :S. typhimuriumATCC 14028SA: Staphy. aureus KCCM 32395 ST: S. typhimurium ATCC 14028
EC :E. coliO157:H7 932 PA :Ps. aeruginosaATCC 27853EC: E. coli 0157: H7 932 PA: Ps. aeruginosa ATCC 27853
표 15. 최소저해농도(mg/㎖)Table 15. Minimum Inhibitory Concentrations (mg / mL)
항균력이란 식품의 저장 및 유통기간을 연장하는 주요한 실험으로 식품의 품질을 변하게 하는 요인으로 미생물, 화학반응 등이 주요한 작용을 하는 요인들이다. 특히 미생물은 부패에 관련하는 미생물, 식품의 안전성에 관여하는 식중독 미생물로 나눌 수 있다. 시료에 대한 페이퍼디스크법으로 실험한 결과 다시마는 항균력이 없었으며, 해당화의 경우 잎은 증류수 추출물, 줄기는 에탄올 추출물, 뿌리는 증류수 추출물에서 항균효과를 나타냈다. 바이오스크린 C 방법을 이용한 최소저해농도 실험결과도 다시마에서는 항균력이 없었으며, 해당화의 경우 잎, 줄기 추출물에서 미약한 항균력이 인정되었다.Antimicrobial activity is a major experiment that extends the storage and distribution period of food, and it is a factor that changes the quality of food, and microorganisms and chemical reactions are the main factors. In particular, microorganisms can be divided into microorganisms related to decay and food poisoning microorganisms involved in food safety. As a result of experiments by paper disc method, kelp had no antimicrobial activity, and in case of glycolysis, leaf showed distilled water extract, stem ethanol extract and root showed distilled water extract. The results of the experiments with the minimum inhibitory concentration using the bioscreen C method also had no antimicrobial activity in kelp, and a weak antimicrobial activity was recognized in the leaves and stem extracts.
한편 본 발명의 해당화 추출물 또는 착즙액을 함유하는 해당화 음료의 제조방법은 해당화 추출물 또는 착즙액, 과당, 레몬농축액, 정백당, 솔비톨, 비타민C 및 정제수를 혼합하는 단계와, 전기의 혼합액을 28∼35℃에서 1∼3시간 동안 균질하게 교반하여 여과하는 단계와, 전기의 여과액을 85∼95℃에서 5∼10초간 살균하는 단계가 포함된 것을 특징으로 한다.On the other hand, the method for producing a glycolytic beverage containing a glycolysis extract or juice of the present invention comprises the steps of mixing glycolysis extract or juice, fructose, lemon concentrate, white sugar, sorbitol, vitamin C and purified water, and the mixture of the above 28-35 It is characterized in that it comprises the step of filtering by stirring uniformly for 1 to 3 hours at ℃, and sterilizing the filtrate of the electric filtrate at 85 to 95 ℃ for 5 to 10 seconds.
상기에서 해당화 추출물 또는 착즙액 5∼15 중량%, 과당 8∼10 중량%, 레몬농축액 0.1∼0.5 중량%, 정백당 0.5∼1.5 중량%, 솔비톨 0.5∼1.5 중량%, 비타민C 0.1∼0.3 중량% 및 정제수 63.4∼83.4 중량%가 함유되거나 또는 해당화 착즙액 10∼15중량%와 머루 과즙 10∼15 중량%, 과당 8∼10중량%, 정백당 1∼3중량%, 솔비톨 1∼3중량%, 탄산나트륨 0.01∼0.03중량% 및 정제수 60∼64 중량%가 함유되도록 한다.5-15% by weight of the corresponding extract or juice, 8-10% by weight fructose, 0.1-0.5% by weight lemon concentrate, 0.5-1.5% by weight per white sugar, 0.5-1.5% by weight sorbitol, 0.1-0.3% by weight vitamin C and 63.4 to 83.4% by weight of purified water or 10-15% by weight of the corresponding juice and 10-15% by weight of fruit juice, 8-10% by weight fructose, 1-3% by weight, sorbitol 1-3% by weight, sodium carbonate 0.01 To 0.03% by weight and 60 to 64% by weight of purified water.
상기에서 해당화 추출물 또는 착즙액, 과당, 정백당, 솔비톨을 제외한 조성물은 예상 가능한 과일이나 채소로부터 얻은 추출물 또는 착즙액이 포함된다.The composition except for the glycolysis extract or juice, fructose, white sugar and sorbitol includes extracts or juices obtained from predictable fruits or vegetables.
또한 본 발명의 또다른 해당화 음료는 해당화 잎 또는 뿌리를 세척하여 건조한 후, 분쇄하여 해당화 엽차, 해당화 곡류엽차, 해당화 뿌리 티백 또는 해당화 과립차로 하는 것을 특징으로 한다.In addition, another glycolinated beverage of the present invention is characterized in that it is washed and dried after washing the corresponding leaves or roots, and the corresponding green tea, the corresponding grains green tea, the corresponding tea root tea bags or granulated tea.
상기에서 해당화 엽차는 해당화 잎을 4초∼12초간 스티밍 또는 블렌칭하여 열처리하고, 해당화 곡류엽차는 열처리된 해당화 잎을 25∼35중량%에 현미 45∼65 중량%, 옥수수 5∼15 중량%를 첨가하여 구성되도록 하고, 해당화 과립차는 해당화 과즙 10∼13 중량% 및 머루과즙 3∼6 중량%에 정제포도당 50∼70 중량%, 유당 14∼34 중량% 및 비타민C 0.1 중량%를 혼합한 후, 과립기에 넣고 35∼55메쉬 크기의 해당화 과립차를 얻는다.In the above, the corresponding green tea is heat treated by steaming or blending the corresponding green leaves for 4 to 12 seconds, and the corresponding green tea leaves are 25 to 35% by weight of the heat-treated green leaves, 45 to 65% by weight of brown rice, and 5 to 15% by weight of corn. The granulated tea was prepared by adding 10-13% by weight of the corresponding fruit juice and 3-6% by weight of the fruit juice, after mixing 50-70% by weight of glucose, 14-34% by weight of lactose and 0.1% by weight of vitamin C. The granulator is placed in the granulated tea with a size of 35 to 55 mesh.
또한, 해당화 뿌리를 분쇄하여 130∼160메쉬 크기로 하여 62.5∼87.5 중량%에 현미 또는 옥수수 12.5∼37.5 중량%를 첨가하여 구성되도록 하여 해당화 음료를 얻는다.In addition, the crushed roots are ground to a size of 130 to 160 mesh so that 62.5 to 87.5% by weight of brown rice or corn 12.5 to 37.5% by weight is added to obtain a hydrated beverage.
한편 본 발명의 해당화 음료와 같이 해당화로부터 추출하여 얻은 해당화 추출물 또는 해당화로부터 착즙하여 얻은 해당화 착즙액을 간기능 개선, 암세포 생육억제, 혈당강하 및 면역활성을 증진시키기 위하여 식품학적 또는 약제학적 조성물로 사용할 수 있다.On the other hand, such as the glycolytic beverages of the present invention, the extract of glycolysis, or the extract of juice from the extract, can be used as a food or pharmaceutical composition for improving liver function, inhibiting cancer cell growth, hypoglycemia and enhancing immune activity. Can be.
이하 실시예를 통하여 본 발명을 설명하고자 한다. 그러나 이들이 본 발명의 기술적 범위를 한정하는 것은 아니다.Through the following examples will be described the present invention. However, these do not limit the technical scope of the present invention.
＜실시예 1＞; 해당화 음료<Example 1>; Applicable Drink
해당화를 정제수로 깨끗이 세척한 후, 1∼3cm 크기로 절단하여 착즙기에 넣고 착즙액을 얻었다. 표 16과 같이 해당화 착즙액 5, 10, 15 중량%에 따른 과당 9 중량%, 레몬농축액 0.4 중량%, 정백당 1 중량%, 솔비톨 1 중량%, 비타민C 0.2 중량%, 정제수 63.4∼83.4 중량%를 넣고 28∼35℃에서 1∼3시간 동안 균질하게 교반하고, 여과하여 85∼95℃에서 5∼10초간 살균한 후, 용기에 저장하였다.After washing the purified flowers with purified water, cut into 1-3cm size and put into juicer to obtain a juice. According to Table 16, 9% by weight fructose, 5% by weight, 10% by weight and 15% by weight of lemon concentrate, 0.4% by weight of lemon concentrate, 1% by weight of sorbitol, 1% by weight of sorbitol, 0.2% by weight of vitamin C and 63.4-8.4% by weight of purified water The mixture was stirred homogeneously for 1 to 3 hours at 28 to 35 ° C, filtered and sterilized at 85 to 95 ° C for 5 to 10 seconds, and then stored in a container.
표 16. 해당화 음료 제조시 재료 혼합비율(단위 : 중량%)Table 16. Mixing ratio of ingredients in the manufacture of corresponding beverages (unit: wt%)
상기의 배합비와 같이 제조한 해당화 음료의 품질특성을 알아보기 위하여 브릭스(Brix), pH, 색도를 측정하였고, 잘 훈련된 관능검사요원 10명으로 하여금 5점척도법으로 색, 맛, 향 및 종합적인 맛 등의 관능검사를 하여 그 결과를 표 17에 나타냈다.Brix, pH, and chromaticity were measured to determine the quality characteristics of the corresponding beverages prepared by the above formulated ratio. Sensory tests such as taste and the like are shown in Table 17.
표 17. 해당화 음료의 품질특성Table 17. Quality Characteristics of Correlated Drinks
*: L, + white, - black, a : +Red, - Green, b :Yellow, -Blue*: L, + white,-black, a: + Red,-Green, b: Yellow, -Blue
**: 1. 아주 나쁘다 2. 나쁘다 3. 보통이다 4. 좋다 5. 아주 좋다**: 1. Very bad 2. Bad 3. Usually 4. Good 5. Very good
해당화 착즙액의 첨가비율을 달리하여 음료를 제조한 결과 착즙액 10 중량% 첨가구가 종합적인 관능검사에서 우수한 것으로 나타났다.The beverages were prepared by varying the addition ratio of glycolytic juice, and the addition of 10% by weight of juice was found to be excellent in the comprehensive sensory test.
상기의 해당화 음료 배합비 중에서 관능검사 결과가 우수한 해당화 착즙액 10중량% 첨가시의 간기능 개선, 혈당강하, 면역활성, 항암 등의 기능성 검정을 하여 표 18에 그 결과를 나타냈다.Table 18 shows the results of functional tests such as liver function improvement, hypoglycemic activity, immune activity, anticancer, etc. when 10 wt% of the glycolytic juice solution having excellent sensory test results in the corresponding glycated beverage compounding ratio.
표 18. 해당화 음료의 기능성 검정 결과(%/㎍/㎖)Table 18. Functional assay results (% / μg / mL) of the corresponding beverages
관능검사에서 양호한 해당화 착즙액 10 중량%를 첨가하여 제조한 음료의 기능성 검정결과, 간기능 개선 측정에서 139%, 혈당강하 67%, 면역활성 138%의 효과가 있는 것으로 나타났다. 그러나, 항암 활성의 경우, 인간 폐암세포에서 53%의 낮은 활성을 나타났다.According to the sensory test, the functional test of the beverage prepared by adding 10% by weight of the corresponding glycolytic juice showed that the effect of improving liver function was 139%, blood sugar drop 67%, and immune activity 138%. However, anti-cancer activity was 53% lower in human lung cancer cells.
＜실시예 2＞; 해당화 + 머루 혼합음료<Example 2>; Matcha + Murume Drink
해당화 착즙액 10∼15 중량%와 머루 과즙 10∼15 중량%을 표 19과 같이 과당9중량%, 정백당 2중량%, 솔비톨 1중량%, 탄산나트륨 0.02중량%, 정제수 62.98 중량%를 넣고 실시예 1과 같이 하여 해당화 및 머루과즙 음료를 얻었다.10-15% by weight of the corresponding juice and 10-15% by weight of the fruit juice were added 9% by weight of fructose, 2% by weight of white sugar, 1% by weight of sorbitol, 0.02% by weight of sodium carbonate, and 62.98% by weight of purified water. In this manner, the corresponding sweetened and squash juice was obtained.
표 19. 재료 혼합비율(단위 : 중량%)Table 19. Material Mixing Ratio (Unit: Weight%)
상기의 배합비와 같이 제조한 해당화와 머루 혼합 음료의 품질특성을 알아 보기 위하여 브릭스, pH, 색도를 측정하였고, 잘 훈련된 관능검사요원 10명으로 하여금 5점척도법으로 색, 맛, 향 및 종합적인 맛의 관능검사를 측정하여 그 결과를 아래의 표 20에 나타냈다.Brix, pH and chromaticity were measured in order to find out the quality characteristics of the ethanol and muru mixed beverage prepared with the above formulated ratio. The taste sensory test was measured and the results are shown in Table 20 below.
표 20. 품질특성Table 20. Quality characteristics
*: L, + white, - black, a : +Red, - Green, b :Yellow, -Blue*: L, + white,-black, a: + Red,-Green, b: Yellow, -Blue
**: 1. 아주 나쁘다 2. 나쁘다 3. 보통이다 4. 좋다 5. 아주 좋다**: 1. Very bad 2. Bad 3. Usually 4. Good 5. Very good
해당화, 머루과즙의 첨가비율을 각각 달리하여 혼합음료를 제조한 결과,Brix, pH, 색도에서는 큰 차이는 나타내지 않았으나, 종합적인 관능검사에서 해당화 착즙액 10 중량%, 머루과즙 15 중량% 첨가구가 양호한 것으로 나타났다.As a result of preparing mixed drinks by varying the ratios of glycolysis and berry fruit juice, there was no significant difference in brix, pH, and chromaticity. However, in the comprehensive sensory test, 10% by weight of nectarized juice and 15% by weight of berry juice were added. Found to be good.
＜실시예 3＞; 해당화 엽차제조<Example 3>; Gyehwahwa green tea production
해당화 잎을 정제수로 깨끗이 세척하여 건조한 후, 0.5∼1.0cm 크기로 절단하여 스티밍 및 블렌칭을 4초∼12초간 실시하여 얻은 엽차를 각각 5g 티백에 넣어 1개씩을 100℃로 끓인 후 70∼80℃로 식힌 물 100㎖에 30초 정도 침출한 후 색도를 측정하고, 잘 훈련된 관능검사요원으로 하여금 관능검사를 통하여 색, 맛, 향기, 기호도를 평가하여 표 21과 같은 결과를 얻었다.After washing the dried flowers with purified water and drying them, cut them into 0.5 ~ 1.0cm size, steaming and blanching for 4 seconds to 12 seconds, and put each green tea into 5g tea bag and boil each one at 100 ℃ and then 70 ~ After leaching in 100 ml of water cooled to 80 ° C. for about 30 seconds, chromaticity was measured, and the well-trained sensory tester evaluated color, taste, aroma, and palatability through the sensory test to obtain a result as shown in Table 21.
표 21. 엽차 제조를 위한 전처리 결과Table 21. Pretreatment results for tea production
*: L, + white, - black, a : +Red, - Green, b :Yellow, -Blue*: L, + white,-black, a: + Red,-Green, b: Yellow, -Blue
** : + 나쁨, ++ 보통, +++ 양호**: + bad, ++ normal, +++ good
해당화 엽차 제조를 위한 잎의 처리방법에 따른 색도 및 관능 검사결과는 색도의 경우 해당화 잎을 스팀으로 8초 처리한 것이 색이 가장 파란계열을 나타내었지만, 관능검사 결과에서는 브랜칭 8초 처리한 잎이 가장 양호한 것으로 나타났다.Chromaticity and sensory test results according to the treatment method of the leaves for the production of the corresponding flower tea showed that the color of the blue color was the highest when the treatment of the corresponding flower leaves with steam for 8 seconds, but the leaves treated with branching 8 seconds in the sensory test results It was found to be the best.
＜실시예 4＞; 해당화 곡류엽차<Example 4>; Grainized Grain Tea
해당화 잎을 깨끗이 세척하고 건조한 후, 실시예 3과 같은 방법으로 처리한 해당화 잎 30 중량%에 현미 45∼65 중량%, 옥수수 5∼15 중량%를 아래의 표 22의 혼합비율로 첨가하여 잘 혼합한 후, 실시예 3과 같이 하여 해당화 곡류엽차를 얻었다.After washing and drying the corresponding flower leaves, mixed with 30% by weight of the corresponding flower leaves in the same manner as in Example 3, 45 to 65% by weight of brown rice and 5 to 15% by weight of corn were added in the mixing ratios of Table 22 below. After that, the grained grain tea was obtained in the same manner as in Example 3.
표 22. 재료 혼합비율(단위 : 중량%)Table 22. Material Mixing Ratio (Unit: Weight%)
상기의 해당화 곡류엽차에 실시예 3과 같이 더운 물에 침출시켜 색도를 측정하고, 잘 훈련된 관능검사요원 10명으로 하여금 5점척도법으로 색, 맛, 향 및 종합적인 맛을 표 23에 나타냈다. 또한 해당화 곡류엽차의 간기능개선효과를 측정해 본 결과, 시료1(해당화 잎 30, 현미 65, 옥수수 5)의 간기능개선효과는 136 (%/1.0mg/ml)를 나타냈다.Chromatization by leaching in the hot water as in Example 3 to the corresponding grain grain tea, 10 well-trained sensory test personnel by the five-point scale method shown in Table 23 the color, taste, aroma and overall taste. In addition, as a result of measuring the liver function improvement effect of the corresponding grain grain tea, the liver function improvement effect of Sample 1 (30 glycolysis leaves, brown rice 65, corn 5) showed 136 (% / 1.0mg / ml).
표 23. 해당화 곡류엽차의 품질특성Table 23. Quality Characteristics of Grainized Grain Teas
*: L, + white, - black, a : +Red, - Green, b :Yellow, -Blue*: L, + white,-black, a: + Red,-Green, b: Yellow, -Blue
**: 1. 아주 나쁘다 2. 나쁘다 3. 보통이다 4. 좋다 5. 아주 좋다**: 1. Very bad 2. Bad 3. Usually 4. Good 5. Very good
해당화 엽차의 부재료로 현미, 옥수수를 첨가하여 차의 품질특성을 조사한 결과 색도에서는 큰 차이를 보이지 않았으나, 관능검사에서는 시료 1(해당화 30 중량%, 현미 65 중량%, 옥수수 5 중량%)의 해당화 곡류엽차에서 기호도가 가장 양호하게 나타났다.As a result of examining the quality characteristics of tea by adding brown rice and corn as a component of the corresponding green tea, there was no significant difference in chromaticity, but in sensory evaluation, the corresponding grains of sample 1 (30% by weight, 65% by weight brown rice, 5% by weight corn) The palatability was the best in the tea.
＜실시예 5＞; 해당화 잎 티백제조<Example 5>; Gyohwa Leaf Tea Bag Manufacturing
해당화 잎을 세척 및 건조한 후 100, 150메쉬(mesh) 크기별로 각각 해당화 티백을 제조하였다. 메쉬별에 따른 추출물의 색도 및 관능검사를 실시하여 표 24에 나타냈다.After washing and drying the corresponding leaves, the corresponding tea bags were prepared for each of 100 and 150 mesh sizes. The chromaticity and sensory test of the extract according to the mesh is shown in Table 24.
표 24. 해당화 티백의 색도 및 관능검사Table 24. Chromaticity and sensory test of the corresponding tea bags
해당화 티백제조를 위해 분쇄를 메쉬별로 달리하여 차를 제조한 후 추출물의 색도와 관능검사를 조사한 결과, 분쇄 메쉬가 조밀할수록 추출물의 색이 짙어 졌으나 조밀한 입자가 부직포 밖으로 나와 관능검사에서는 150메쉬 이상으로 분쇄한 입자가 좋은 것으로 나타났다.Tea was prepared by varying the pulverization by mesh for the production of the corresponding tea bags, and the color and sensory test of the extracts showed that the denser the crushed mesh, the thicker the extract was. It was found that the particles pulverized with good.
＜실시예 6＞; 해당화 뿌리 티백제조<Example 6>; Gypsum root tea bag production
해당화 뿌리를 세척하고 건조한 후, 분쇄기에서 분쇄하여 150메쉬 크기만을 골라 62.5∼87.5 중량%에 옥수수 12.5∼37.5 중량%를 넣고 해당화 뿌리를 각각 5g 티백에 넣어 아래의 표 25의 혼합비율과 같이 제조하였다.After washing and drying the glycolysis roots, pulverized in a grinder to pick only the size of 150 mesh, 62.5 to 87.5% by weight of corn 12.5 to 37.5% by weight and put the respective roots in 5g tea bags prepared according to the mixing ratio of Table 25 below .
표 25. 해당화 뿌리와 옥수수의 혼합비율(%)Table 25. Percentage Mix of Roots and Corn
해당화 뿌리 티백을 대상으로 색도를 측정하고, 잘 훈련된 관능검사요원 10명으로 하여금 5점척도법으로 색, 맛, 향 및 종합적인 맛의 관능검사(끓는 물 1ℓ에 티백을 넣은 후 15분간 추출 후 음용)를 실시하여 그 결과를 아래의 표 26에 나타냈다.Chromatography was measured on the tea bag with the root of the flower, and 10 well-trained sensory testers used five-point scales to test color, taste, aroma, and overall taste. Drinking), and the results are shown in Table 26 below.
표 26. 해당화 뿌리 티백의 품질특성Table 26. Quality Characteristics of Gypsum Root Tea Bags
*: L, + white, - black, a : +Red, - Green, b :Yellow, -Blue*: L, + white,-black, a: + Red,-Green, b: Yellow, -Blue
**: 1. 아주 나쁘다 2. 나쁘다 3. 보통이다 4. 좋다 5. 아주 좋다**: 1. Very bad 2. Bad 3. Usually 4. Good 5. Very good
상기의 해당화 뿌리 62.5 중량%를 사용한 티백을 대상으로 혈당강하, 면역활성, 항암 기능을 측정하여 그 결과를 표 27에 나타냈다.The blood sugar drop, immune activity, and anticancer function were measured for the tea bags using 62.5% by weight of the corresponding roots, and the results are shown in Table 27.
표 27. 해당화 티백의 기능성 검정 결과(%/㎎/㎖)Table 27. Results of functional assay of glycolytic tea bags (% / mg / ml)
옥수수를 부재료로 사용하여 해당화 티백을 제조한 결과 해당화 75 중량% 첨가시 추출물의 색도는 짙어 졌으나, 75 중량% 이상 첨가시에는 부직포내 부피증가로 인해 추출이 잘되지 않았고, 관능검사에서는 해당화 뿌리 62.5 중량% 첨가구가 가장 양호한 것으로 나타났다.As a result of preparing cornified tea bag using corn as a subsidiary material, the color of the extract became thicker when 75% by weight of glycolysis was added, but when it was added more than 75% by weight, the extraction was not good due to the volume increase in the nonwoven fabric. The weight percent additions were found to be the best.
해당화 뿌리 62.5 중량% 첨가한 티백 추출물의 기능성을 검정한 결과 혈당강하 68, 면역활성 123, 항암활성이 49%로 나타나 음료수로서의 개발가능성이 매우 높게 나타났다.As a result of testing the functionality of the tea bag extract added with 62.5% by weight of the corresponding root, the hypoglycemic activity was 68, the immune activity was 123, and the anticancer activity was 49%.
＜실시예 7＞; 해당화 과립차 제조<Example 7>; Granulated tea production
해당화 열매를 정제수로 세척하고 건조한 후, 분쇄기에 넣고 분쇄하여 과즙을 얻어 여과한 해당화 과즙 10∼13 중량%, 머루과즙 3∼6 중량%에 정제포도당 45∼70 중량%, 유당 14∼34 중량% 및 비타민C 0.1 중량%를 혼합한 후, 과립기에 넣고 50메쉬 크기의 해당화 과립차를 얻었다. 표 28의 배합비에 상세한 배합비를 나타냈다.The dried fruit was washed with purified water, dried, put into a grinder, pulverized to obtain a juice, and then filtered from 10 to 13% by weight of filtered fruit juice, 3 to 6% by weight of fruit juice, 45 to 70% by weight of refined glucose, and 14 to 34% by weight of lactose. And 0.1% by weight of vitamin C was mixed, and then put into a granulator to obtain a granulated tea of 50 mesh size. The compounding ratio detailed in the compounding ratio of Table 28 was shown.
표 28. 해당화 과립차의 재료 혼합비율(단위 : 중량%)Table 28. Material mixing ratio of granular tea (unit: wt%)
상기의 재료 혼합비율에 따른 해당화 과립차의 품질특성을 알아 보기 위하여 브릭스, 용해도, 색도, 수율을 측정하였고, 잘 훈련된 관능검사요원 10명으로 하여금 5점척도법에 따라 색, 향, 맛 및 종합적인 기호도를 평가하여 표 29에 그 결과를 나타냈다.Brix, solubility, chromaticity, and yield were measured to determine the quality characteristics of the granular tea according to the mixing ratio of the above ingredients. The degree of preference was evaluated and the result was shown in Table 29.
표 29. 해당화 과립차의 품질특성Table 29. Quality characteristics of granulated tea
*: L, + white, - black, a : +Red, - Green, b :Yellow, -Blue*: L, + white,-black, a: + Red,-Green, b: Yellow, -Blue
**: 1. 아주 나쁘다 2. 나쁘다 3. 보통이다 4. 좋다 5. 아주 좋다**: 1. Very bad 2. Bad 3. Usually 4. Good 5. Very good
해당화 과즙을 첨가한 과립차의 품질특성을 조사한 결과, Brix, 용해도, 색도, 수율등은 처리에 따라 큰 차이를 보이지 않았으나 관능검사 결과에서는 머루과즙, 정제포도당 등의 첨가량이 증가할수록 기호도가 증가하였다.The quality characteristics of granulated teas with added perilla fruit juice did not show significant differences according to the treatment, but the degree of preference increased as the amount of added fruit juice and refined glucose increased.
본 발명은 해당화의 약리적 기능을 유지하면서 관능적인 기호성을 향상시켜 해당화 음료, 해당화 엽차, 해당화 티백, 해당화 과립차 등으로 개발함으로써 해당화를 손쉽게 음용할 수 있도록 함과 동시에 질병예방 효과도 거둘 수 있다.The present invention improves the sensory palatability while maintaining the pharmacological function of the corresponding flower to develop the corresponding drink, the corresponding tea, the corresponding tea bag, the corresponding tea granule tea, etc., so that the corresponding flower can be easily consumed and disease prevention effects can be achieved.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2001-0001897A KR100414393B1 (en) | 2001-01-12 | 2001-01-12 | Manufacturing Method for Tea and Beverage Using Rosa rugosa Thunberg |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2001-0001897A KR100414393B1 (en) | 2001-01-12 | 2001-01-12 | Manufacturing Method for Tea and Beverage Using Rosa rugosa Thunberg |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20010110069A KR20010110069A (en) | 2001-12-12 |
| KR100414393B1 true KR100414393B1 (en) | 2004-01-07 |
Family
ID=45928521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2001-0001897A KR100414393B1 (en) | 2001-01-12 | 2001-01-12 | Manufacturing Method for Tea and Beverage Using Rosa rugosa Thunberg |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100414393B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102005795B1 (en) * | 2018-03-19 | 2019-07-31 | 농업회사법인 주식회사 다도락 | Method for producng functional tea using Cudrania tricuspidata |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100495943B1 (en) * | 2002-11-15 | 2005-06-16 | 강원도 고성군 (관리부서 농업기술센터) | Method for Menufacture of Wild grapes Wine |
| KR100767799B1 (en) * | 2005-06-30 | 2007-10-18 | 강원도 | Powdered tea with meoru fruit and preparation method thereof |
| KR100927431B1 (en) * | 2007-10-16 | 2009-11-19 | 연세대학교 산학협력단 | Composition for preventing or treating cancer, including glycolysis stem extract |
| KR101006375B1 (en) * | 2010-06-28 | 2011-01-05 | 전라남도 | Method for producing leaf tea of Rugosa rose having anti-diabetic and anti-oxidant efficacy |
| KR101358718B1 (en) * | 2011-06-10 | 2014-02-10 | 연세대학교 산학협력단 | Cosmetic composition which has ricinus communis l. extract and sophora japonica flower extract as active components, and improves cellulite |
| KR101696342B1 (en) * | 2014-02-19 | 2017-01-13 | 동신대학교산학협력단 | Composition for Anti-Diabetes |
| KR101662281B1 (en) * | 2015-11-04 | 2016-10-05 | 김태현 | process of jerusalem artichoke-wild ginseng drink and jerusalem artichoke-wild ginseng drink there by the same that |
| KR102147058B1 (en) * | 2019-08-05 | 2020-08-24 | 최면 | Composition for prevention, improvement or treatment of diabetes with extracts from Scrophularia Buergeriana, Siberian ginseng, Lycii fructus root, Momordica charantia Linnaeus, Rosa rugosa |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR860002155A (en) * | 1984-08-03 | 1986-03-26 | 사바 쇼오이징 | Semiconductor devices |
| JPH04271770A (en) * | 1991-02-27 | 1992-09-28 | Asahi:Kk | Tea |
| KR0173814B1 (en) * | 1995-08-24 | 1999-02-01 | 전기엽 | Health aid food comprising the extract of rosa rugosa thunb |
| KR19990033613A (en) * | 1997-10-25 | 1999-05-15 | 박원훈 | Use of beta-glucogallin compounds as antioxidants and methods for their isolation and purification |
| KR19990053259A (en) * | 1997-12-24 | 1999-07-15 | 전기엽 | Extract of the periflora and its manufacturing method |
-
2001
- 2001-01-12 KR KR10-2001-0001897A patent/KR100414393B1/en not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR860002155A (en) * | 1984-08-03 | 1986-03-26 | 사바 쇼오이징 | Semiconductor devices |
| JPH04271770A (en) * | 1991-02-27 | 1992-09-28 | Asahi:Kk | Tea |
| KR0173814B1 (en) * | 1995-08-24 | 1999-02-01 | 전기엽 | Health aid food comprising the extract of rosa rugosa thunb |
| KR19990033613A (en) * | 1997-10-25 | 1999-05-15 | 박원훈 | Use of beta-glucogallin compounds as antioxidants and methods for their isolation and purification |
| KR19990053259A (en) * | 1997-12-24 | 1999-07-15 | 전기엽 | Extract of the periflora and its manufacturing method |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102005795B1 (en) * | 2018-03-19 | 2019-07-31 | 농업회사법인 주식회사 다도락 | Method for producng functional tea using Cudrania tricuspidata |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010110069A (en) | 2001-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101974723B1 (en) | Beverage of bitter melon and fruit-vegetable mixture with excellent palatability and high GABA and high functionality fermented by Lactobacillus plantarum and Lactobacillus brevis | |
| KR102386296B1 (en) | Complex-fermented composition of Fabaton soybean leaves and Schisandra chinensis having enhanced anti-diabetic and anti-obesity effects and preparation method thereof | |
| KR101432584B1 (en) | Method for steamed and fermented Codonopsis lanceolata for boosting biological activity | |
| KR100414393B1 (en) | Manufacturing Method for Tea and Beverage Using Rosa rugosa Thunberg | |
| KR20010069130A (en) | Manufacturing Method for Extracts of Bamboo Leaves and Use Thereof | |
| KR101996466B1 (en) | Method for producing healthful pear juice comprising green tea concentrate | |
| KR101962766B1 (en) | Improving method for bitter taste of bitter gourd liquid tea and preparing method for bitter taste improved bitter gourd liquid tea using the same | |
| JP4031544B2 (en) | Chlorophylase inhibitor, food, feed and cosmetics containing the same | |
| KR101276157B1 (en) | Method and culture composition for manufacturing fast-fermented bean paste capable of improving color and flavor with having antioxidative activity and anti-diabetic activity | |
| KR101646516B1 (en) | Food composition comprising extract of nelumbo nucifera leaf, seed, and olive leaf | |
| KR100402421B1 (en) | Manufacturing Method for Beverage Using Crataegue pinnatifida | |
| KR100536083B1 (en) | Mixture of pine tree leaves supernatant juice fermentation solution and Lespedeza cuneate G. Don extract and health food containing the same | |
| KR20210143499A (en) | Manufacturing method of health food having antioxidant activity containing fermented polygonum multiflorum complex extracts and the health food having antioxidant activity thereby | |
| KR100458300B1 (en) | Drink Composition Containing Extracts of Gastrodia elata Blum | |
| KR20150037774A (en) | Preparation of clove having enhanced antioxidative effect | |
| KR100529997B1 (en) | Functional Composition Containing Extracts of Fruits of Hovenia dulcis var.koreana | |
| KR101146115B1 (en) | Beverage containing fermened extract of rhus verniciflura having anticancerous and antioxidative activity, and the preparation method thereof | |
| KR102444816B1 (en) | Preparing method of the functional rice paste using mulberry leaves, mulberry and glutinous rice | |
| KR100428480B1 (en) | Manufacturing Method for Pumpkin Wine | |
| KR101935538B1 (en) | Mixture of extract or fermentation using Allium tuberosum and production method thereof | |
| KR100423100B1 (en) | Manufacturing Method for Cardamine Komarovi Sauce | |
| KR100536086B1 (en) | Mixture of pine tree leaves extract and barley germs leaves and health food containing the same | |
| KR100516888B1 (en) | Beverage of Sorbus commixta and manufacturing method thereof | |
| TW201114374A (en) | Goya koji composition | |
| KR20160026380A (en) | Expansion Fruit Tea bag |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| G15R | Request for early publication | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| G170 | Re-publication after modification of scope of protection [patent] | ||
| FPAY | Annual fee payment |
Payment date: 20120119 Year of fee payment: 9 |
|
| LAPS | Lapse due to unpaid annual fee |